NeuroNOS Releases Research Publication By Its CSO Demonstrating Mechanism Of Action In Alzheimer's Disease

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early stages of Alzheimer's disease (AD), offers new hope for the development of effective therapies for this devastating condition. A copy of the article is available on Translational Psychiatry website at (click here).

Alzheimer's disease is one of the most common and costly neurodegenerative disorders globally, affecting over 55 million people and imposing a staggering economic burden exceeding $1 trillion annually. Beyond its financial toll, AD devastates families, progressively eroding the identity and autonomy of those afflicted. Despite decades of research, there remains no truly effective treatment capable of halting or reversing the disease's progression.

The research discussed in the article identifies significant disruptions in nitric oxide (NO)-related pathways, particularly in S-nitrosylation, a key post-translational modification mediated by NO. The research demonstrates early and consistent molecular changes across two established AD mouse models, highlighting the role of nitrosative stress, impaired neurotransmission, and mTOR hyperactivation. Importantly, the data suggest that targeted inhibition of NO production may serve as a promising therapeutic strategy in early-stage Alzheimer's disease.

"The results of this study validate a key component of our scientific vision," said Prof. Amal. "We have demonstrated, for the first time, a shared mechanism in Alzheimer's models rooted in nitric oxide dysregulation. These results strengthen our confidence in the potential of NO modulation as a therapeutic approach and further establish the robustness of our CNS drug development platform."

"NeuroNOS is a young and radically innovative company, built to think differently and move fast," added Amir Avniel, CEO of NeuroNOS. "In a remarkably short time, we have transitioned from scientific vision to tangible reality—decoding one of the most critical mechanisms in brain diseases and constructing a drug development platform around it. We are already in advanced stages of formulation development and manufacturing, preparing for clinical trials. The brain disease arena is in dire need of breakthroughs, and we have embraced the unique mission to lead this innovative development of brain therapeutics."